DK1200073T3 - Selektive iGluR5-receptorantagonister til behandling af migræne - Google Patents

Selektive iGluR5-receptorantagonister til behandling af migræne

Info

Publication number
DK1200073T3
DK1200073T3 DK00944671T DK00944671T DK1200073T3 DK 1200073 T3 DK1200073 T3 DK 1200073T3 DK 00944671 T DK00944671 T DK 00944671T DK 00944671 T DK00944671 T DK 00944671T DK 1200073 T3 DK1200073 T3 DK 1200073T3
Authority
DK
Denmark
Prior art keywords
migraine
treatment
receptor antagonists
iglur5 receptor
selective iglur5
Prior art date
Application number
DK00944671T
Other languages
English (en)
Inventor
David Bleakman
Paul Leslie Ornstein
Amy Suzon Chappell
Sandra Ann Filla
Kirk Willis Johnson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1200073T3 publication Critical patent/DK1200073T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK00944671T 1999-07-06 2000-06-27 Selektive iGluR5-receptorantagonister til behandling af migræne DK1200073T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14248599P 1999-07-06 1999-07-06
US15116599P 1999-08-27 1999-08-27
PCT/US2000/016297 WO2001001972A2 (en) 1999-07-06 2000-06-27 SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE

Publications (1)

Publication Number Publication Date
DK1200073T3 true DK1200073T3 (da) 2007-05-07

Family

ID=26840135

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00944671T DK1200073T3 (da) 1999-07-06 2000-06-27 Selektive iGluR5-receptorantagonister til behandling af migræne

Country Status (28)

Country Link
US (4) US6566370B1 (da)
EP (1) EP1200073B1 (da)
JP (1) JP4619595B2 (da)
KR (1) KR20020024300A (da)
CN (1) CN1230174C (da)
AR (1) AR029373A1 (da)
AU (1) AU773304B2 (da)
BR (1) BR0012175A (da)
CA (1) CA2378613C (da)
CZ (1) CZ20014488A3 (da)
DE (1) DE60032905T2 (da)
DK (1) DK1200073T3 (da)
DZ (1) DZ3209A1 (da)
EA (1) EA004290B1 (da)
ES (1) ES2278619T3 (da)
HK (1) HK1047036A1 (da)
HR (1) HRP20020013A2 (da)
HU (1) HUP0202253A3 (da)
IL (1) IL146697A0 (da)
MX (1) MXPA01012726A (da)
MY (1) MY133503A (da)
NO (1) NO20016246L (da)
NZ (1) NZ515616A (da)
PE (1) PE20010299A1 (da)
PT (1) PT1200073E (da)
SK (1) SK112002A3 (da)
TR (1) TR200200066T2 (da)
WO (1) WO2001001972A2 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1257545A1 (en) * 1999-12-22 2002-11-20 Eli Lilly And Company SELECTIVE iGLUR 5? RECEPTOR ANTAGONISTS
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
US6855725B2 (en) * 2001-01-05 2005-02-15 Eli Lilly And Company Excitatory amino acid receptor antagonists
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
CZ20031856A3 (cs) * 2001-01-05 2003-09-17 Eli Lilly And Company Antagonisté receptorů excitačních aminokyselin
AU2002241565A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US6953805B2 (en) * 2001-01-05 2005-10-11 Eli Lilly And Company Excitatory amino acid receptor antagonists
MXPA03005982A (es) * 2001-01-05 2003-09-10 Lilly Co Eli Antagonistas de receptores de aminoacidos excitadores.
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US20040082606A1 (en) * 2001-12-20 2004-04-29 Khau Vien Van Excitatory amino acid receptor antagonists
DK1511741T3 (da) 2002-04-26 2013-01-21 Lilly Co Eli Esterderivater af en decahydroisoquinolin-3-carboxylsyre som analgetika
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
BRPI0716715B1 (pt) 2006-08-23 2021-07-06 Xenon Pharmaceuticals, Inc Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula
US8722929B2 (en) 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8030518B2 (en) 2006-11-28 2011-10-04 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP3661500B1 (en) 2017-07-31 2026-01-07 Novartis AG Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
MA53338A (fr) 2018-03-05 2022-01-05 Janssen Pharmaceutica Nv Dosages pour détecter la neurodégénérescence
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
CN114667146A (zh) 2019-11-08 2022-06-24 泽农医药公司 治疗抑郁症的方法
PE20231815A1 (es) 2021-02-09 2023-11-16 Xenon Pharmaceuticals Inc Abridor de canales de potasio controlado por voltaje para uso en el tratamiento de la anhedonia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
WO1998045270A1 (en) * 1997-04-07 1998-10-15 Eli Lilly And Company Pharmacological agents
ATE240299T1 (de) * 1999-07-06 2003-05-15 Lilly Co Eli Diester prodrugs von decahydroischinoline-3- carbonsäure

Also Published As

Publication number Publication date
US6759418B2 (en) 2004-07-06
AU773304B2 (en) 2004-05-20
TR200200066T2 (tr) 2002-04-22
SK112002A3 (en) 2003-05-02
MXPA01012726A (es) 2002-07-02
EA004290B1 (ru) 2004-02-26
NZ515616A (en) 2004-05-28
EA200200132A1 (ru) 2002-06-27
HRP20020013A2 (en) 2003-08-31
NO20016246L (no) 2002-03-04
AU5873200A (en) 2001-01-22
HK1047036A1 (zh) 2003-02-07
IL146697A0 (en) 2002-07-25
PE20010299A1 (es) 2001-03-07
US6566370B1 (en) 2003-05-20
EP1200073B1 (en) 2007-01-10
PT1200073E (pt) 2007-03-30
US7157582B2 (en) 2007-01-02
WO2001001972A3 (en) 2001-12-06
US20050159445A1 (en) 2005-07-21
NO20016246D0 (no) 2001-12-19
CA2378613C (en) 2007-10-02
ES2278619T3 (es) 2007-08-16
BR0012175A (pt) 2002-03-05
CN1359289A (zh) 2002-07-17
HUP0202253A3 (en) 2003-12-29
DZ3209A1 (fr) 2001-01-11
JP4619595B2 (ja) 2011-01-26
WO2001001972A2 (en) 2001-01-11
DE60032905T2 (de) 2007-10-18
HUP0202253A2 (hu) 2002-11-28
US20040192722A1 (en) 2004-09-30
US6855823B2 (en) 2005-02-15
EP1200073A2 (en) 2002-05-02
US20030199546A1 (en) 2003-10-23
CN1230174C (zh) 2005-12-07
JP2003503449A (ja) 2003-01-28
CA2378613A1 (en) 2001-01-11
KR20020024300A (ko) 2002-03-29
AR029373A1 (es) 2003-06-25
MY133503A (en) 2007-11-30
DE60032905D1 (de) 2007-02-22
CZ20014488A3 (cs) 2003-01-15

Similar Documents

Publication Publication Date Title
DK1339678T3 (da) Selektive agonister til EP4-receptor til behandling af osteoporose
NO20016246L (no) Selektiv iGluR5 reseptorantagonist for behandling av migrene
EE200200355A (et) EP4 retseptori selektiivsed agonistid osteoporoosi raviks
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
CY2010003I2 (el) Αγωνιστες των βητα-2 αδρενεργικων υποδοχεων
DE60026169D1 (de) Selektive neurokinin-antagonisten
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1143977T3 (da) 2-oxy-benzoxazinonderivater til behandling af obesitas
DK1221952T3 (da) Anvendelse af en antagonist til centrale cannaboidreceptorer med henblik på fremstilling af lægemidler
NO20015779L (no) Bradykinin-reseptorantagonister
NO20013997D0 (no) Reseptoranalyse
NO20016053L (no) IL-8 reseptor-antagonister
DK1187833T3 (da) Fremgangsmåde til fremstilling af thiamethoxam
NO20016052L (no) IL-8-reseptor-antagonister
DK1180028T3 (da) IL-8-receptorantagonister
DK1121356T3 (da) 3-tetrahydropyridin-4-yl-indoler til behandling af psykotiske lidelser
ATE284870T1 (de) Antagonisten des vitronectin-receptors
NO20015774L (no) IL-8 reseptorantagonister
NO20021295L (no) Nikotinsyreacetylcholin-reseptor
IS5897A (is) Úreídópíperidín afleiður sem valvís NK3 viðtakamótlyf fyrir manneskjur
DK1500396T3 (da) Reboxetin til behandling af migrænehovedpiner
DK1468686T3 (da) S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser
DK1451177T3 (da) Substituerede 2-pyrrolidin-2-yl-1H-indol-derivater til behandling af migræne
NO20022142L (no) Anvendelse av dopamin-D3 reseptor agonister for behandling av saltavhengig hypertensjon
NO20016065L (no) IL-8-reseptor-antagonister